How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,516 results for

Vitiligo

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. "Vitiligo and major depressive disorder: a bidirectional population-based cohort study". (PubMed)

"Vitiligo and major depressive disorder: a bidirectional population-based cohort study". Vitiligo patients often report their mental health has an impact on their skin. However, it is unknown as to whether a common mental disorder such as major depressive disorder (MDD) can also precipitate the onset of vitiligo.Evaluate a bidirectional relationship between MDD and vitiligo using The Health Improvement Network (THIN) database.Incident MDD and referent cohorts were followed until the development (...) of vitiligo. Additionally, incident vitiligo and referent cohorts were followed until the development of MDD. Cox proportional-hazards models were used, adjusting for numerous covariates.In adjusted models, MDD patients (n=405,397) were at a 64% increased risk of vitiligo (HR=1.64, 95%CI: 1.43-1.87, p<0.0001) compared to the referent cohort (n=5,739,048). This risk was decreased in patients using antidepressants. Compared to the referent cohort (n=6,137,696), patients with vitiligo (n= 7,104) that were

2018 Journal of American Academy of Dermatology

182. Janus Kinase 1 in Vitiligo & Psoriasis

Janus Kinase 1 in Vitiligo & Psoriasis Janus Kinase 1 in Vitiligo & Psoriasis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Janus Kinase 1 in Vitiligo & Psoriasis The safety and scientific validity (...) of JAK1 in both vitiligo and psoriasis patients before and after treatment with NB-UVB which is considered a gold standard therapy for both diseases. Condition or disease Intervention/treatment Phase Vitiligo Other: skin biopsy Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 30 participants Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Other Official

2018 Clinical Trials

183. Blood endotyping distinguishes the profile of vitiligo from other inflammatory and autoimmune skin diseases. (PubMed)

Blood endotyping distinguishes the profile of vitiligo from other inflammatory and autoimmune skin diseases. Peripheral blood skin-homing/cutaneous lymphocyte antigen (CLA)+ T cells emerge as biomarkers of cutaneous immune activation in patients with inflammatory skin diseases (atopic dermatitis [AD] and alopecia areata [AA]). However, blood phenotyping across these subsets is not yet available in patients with vitiligo.We sought to measure cytokine production by circulating skin-homing (CLA (...) +) versus systemic (CLA-) "polar" CD4+/CD8+ ratio and activated T-cell subsets in patients with vitiligo compared with patients with AA, AD, or psoriasis and control subjects.Flow cytometry was used to measure levels of the cytokines IFN-γ, IL-13, IL-9, IL-17, and IL-22 in CD4+/CD8+ T cells in the blood of 19 patients with moderate-to-severe nonsegmental/generalized vitiligo, moderate-to-severe AA (n = 32), psoriasis (n = 24), or AD (n = 43) and control subjects (n = 30). Unsupervised clustering

2018 Journal of Allergy and Clinical Immunology

184. Molecular and cellular basis of depigmentation in vitiligo patients. (PubMed)

Molecular and cellular basis of depigmentation in vitiligo patients. Vitiligo is a chronic skin disease characterized by the appearance of zones of depigmentation. It is mostly described as an autoimmune disease in which the immune system destroys the melanocytes. Consistent with this origin, genetic studies have implicated genes encoding proteins mediating the immune response targeting melanocytes in the aetiology of this disease, together with proteins specific to these cells. However (...) , the destruction of melanocytes by the immune system is neither global nor complete, because the patients do not display total depigmentation. The etiopathology of vitiligo is clearly complex and cannot be simply reduced to an autoimmune reaction directed against pigmented cells. Intrinsic changes have been observed in the melanocytes, keratinocytes and dermal cells of vitiligo patients. Identification of the molecular and cellular changes occurring in normally pigmented skin in vitiligo patients

Full Text available with Trip Pro

2018 Experimental Dermatology

185. Vitiligo

Vitiligo Vitiligo - NICE CKS Clinical Knowledge Summaries Share Vitiligo: Summary Vitiligo is an acquired, chronic depigmentation disorder characterized by white patches on the skin. It is classified according to its distribution and extent. Non-segmental vitiligo is the more common form, accounting for 85–90% of people with vitiligo. It has a non-dermatomal distribution and is usually generalized and symmetrical. Segmental vitiligo is less common than non-segmental vitiligo and affects 30 (...) % of children with vitiligo. It usually has a dermatomal distribution and is typically unilateral and limited to one segment. Vitiligo is caused by the loss of functioning melanocytes (pigment cells) in the skin, resulting in patches of white skin or hair. Genetic and environmental factors are both thought to be important. The prevalence of vitiligo in the worldwide population is approximately 0.5–2%. The mean age of onset is 20 years of age. Complications include psychosocial problems (including low self

2016 NICE Clinical Knowledge Summaries

186. Triple-combination treatment with oral α-lipoic acid, betamethasone injection, and NB-UVB for non-segmental progressive vitiligo. (PubMed)

Triple-combination treatment with oral α-lipoic acid, betamethasone injection, and NB-UVB for non-segmental progressive vitiligo. Vitiligo is an acquired depigmenting disease with uncertain etiopathogenesis and the treatment modalities need to be consistently updated.To evaluate a triple-combination treatment with oral α-lipoic acid (ALA), betamethasone injection, and narrowband ultraviolet B (NB-UVB) on vitiligo.Patients with non-segmental and progressive vitiligo lesions were randomly (...) assigned to two groups. The treatment group and the control group were respectively treated with oral ALA and placebo, in combination with betamethasone injection and NB-UVB. The effectiveness and adverse events were evaluated by investigators and patients before and after treatment.Fifty non-segmental progressive vitiligo patients were enrolled in the study. The treatment period was 6 months. In treatment group, over 40% patients achieved > 50% improvement and ≥ 5 satisfaction score by 3-month therapy

2017 Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology

187. New approach in the treatment of refractory vitiligo: CO (PubMed)

New approach in the treatment of refractory vitiligo: CO The aim of this study is to evaluate the use of fractional carbon dioxide laser (CO2 ) with betamethasone and salicylic acid solution in the treatment of patients with refractory vitiligo in hands. Each hand of the patient was randomly assigned to one of two groups: lesion treated with fractional carbon dioxide laser associated with betamethasone and salicylic acid solution administration or lesion treated only with betamethasone (...) and salicylic acid solution. We conclude that combined treatment with fractional carbon dioxide laser and betamethasone associated with salicylic acid solution could effectively and safely be used in the treatment of refractory vitiligo.© 2016 Wiley Periodicals, Inc.

2017 Dermatologic therapy

188. Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO

Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Repigmentation Using (...) Apremilast and Phototherapy In Diffuse VITILIGO (Rapid Vitiligo) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03036995 Recruitment Status : Active, not recruiting First Posted : January 31, 2017 Last Update Posted : January 15, 2019 Sponsor: Centre Hospitalier Universitaire de Nice Information provided

2017 Clinical Trials

189. ReNovaCell in Non-segmental Vitiligo

ReNovaCell in Non-segmental Vitiligo ReNovaCell in Non-segmental Vitiligo - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. ReNovaCell in Non-segmental Vitiligo The safety and scientific validity (...) by (Responsible Party): Netherlands Institute for Pigment Disorders Study Details Study Description Go to Brief Summary: Rationale: Autologous epidermal cell suspension grafting is an effective method of surgical treatment in vitiligo, which is suitable for treating large areas with good cosmetic results. The RenovaCell Autologous Cell Harvesting Device (Avita Medical Europe Limited, Cambridge, UK) (previous name: ReCell) is a device which, compared to other forms of autologous epidermal cell suspension

2017 Clinical Trials

190. Comparison of Cyclic On-off and Continuous Excimer Laser Treatment for Vitiligo

Comparison of Cyclic On-off and Continuous Excimer Laser Treatment for Vitiligo Comparison of Cyclic On-off and Continuous Excimer Laser Treatment for Vitiligo - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Comparison of Cyclic On-off and Continuous Excimer Laser Treatment for Vitiligo The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03047733 Recruitment Status : Completed First Posted : February 9, 2017 Last Update Posted : February 9, 2017 Sponsor: Ajou University School of Medicine Information provided

2017 Clinical Trials

191. Repigmentation of Human Vitiligo Skin by NBUVB is Controlled by Transcription of GLI1 and Activation of β-Catenin Pathway in the Hair Follicle Bulge Stem Cells. (PubMed)

Repigmentation of Human Vitiligo Skin by NBUVB is Controlled by Transcription of GLI1 and Activation of β-Catenin Pathway in the Hair Follicle Bulge Stem Cells. Vitiligo repigmentation is a complex process in which the melanocyte-depleted interfollicular epidermis is repopulated by melanocyte precursors from hair follicle bulge that proliferate, migrate, and differentiate into mature melanocytes on their way to the epidermis. The strongest stimulus for vitiligo repigmentation is narrow-band UVB (...) (NBUVB), but how the hair follicle melanocyte precursors are activated by UV light has not been extensively studied. To better understand this process, we developed an application that combined laser capture microdissection and subsequent whole transcriptome RNA sequencing of hair follicle bulge melanocyte precursors and compared their gene signatures to that of regenerated mature epidermal melanocytes from NBUVB-treated vitiligo skin. Using this strategy, we found up-regulation of TNC, GJB6

2017 Journal of Investigative Dermatology

192. UVA1 Phototherapy in Acral Vitiligo

UVA1 Phototherapy in Acral Vitiligo UVA1 Phototherapy in Acral Vitiligo - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. UVA1 Phototherapy in Acral Vitiligo The safety and scientific validity of this study (...) in the treatment of acral vitiligo. Condition or disease Intervention/treatment Phase Acral Vitiligo Other: phototherapy Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 20 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Treatment Official Title: The Role of Long Wavelength UVA1 Phototherapy in Acral Vitiligo Actual Study Start Date : November

2017 Clinical Trials

193. Selenium, zinc, copper, Cu/Zn ratio and total antioxidant status in the serum of vitiligo patients treated by narrow-band ultraviolet B phototherapy. (PubMed)

Selenium, zinc, copper, Cu/Zn ratio and total antioxidant status in the serum of vitiligo patients treated by narrow-band ultraviolet B phototherapy. Vitiligo is a chronic, depigmenting skin disorder, whose pathogenesis is still unknown. Narrow band ultraviolet-B (NB-UVB) is now one of the most widely used treatment of vitiligo. It was suggested that trace elements may play a role in pathogenesis of vitiligo.The aim of this study was to estimate the concentration of selenium (Se), zinc (Zn (...) ), copper (Cu) and Cu/Zn ratio as well as total antioxidant status (TAS) in the serum of patients with vitiligo.We assessed 50 patients with vitiligo and 58 healthy controls. Serum levels of Se, Zn and Cu were determined by the atomic absorption spectrometry method, and the Cu/Zn ratio was also calculated. TAS in serum was measured spectrophotometrically.Serum concentration of Se in patients with vitiligo before and after phototherapy was significantly lower as compared to the control group. Zn level

2017 Journal of Dermatological Treatment

194. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. (PubMed)

Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. Vitiligo is an autoimmune disease in which cutaneous depigmentation occurs. Existing therapies are often inadequate. Prior reports have shown benefit of the Janus kinase (JAK) inhibitors.To evaluate the efficacy of the JAK 1/3 inhibitor tofacitinib in the treatment of vitiligo.This is a retrospective case series of 10 consecutive patients with vitiligo treated with tofacitinib (...) regeneration.Limitations include the small size of the study population, retrospective nature of the study, and lack of a control group.Treatment of vitiligo with JAK inhibitors appears to require light exposure. In contrast to treatment with phototherapy alone, repigmentation during treatment with JAK inhibitors may require only low-level light. Maintenance of repigmentation may be achieved with JAK inhibitor monotherapy. These results support a model wherein JAK inhibitors suppress T cell mediators of vitiligo

Full Text available with Trip Pro

2017 Journal of American Academy of Dermatology

195. Effects of age of onset on disease characteristics in non-segmental vitiligo. (PubMed)

Effects of age of onset on disease characteristics in non-segmental vitiligo. In patients with vitiligo, the clinical and laboratory features of the disease may vary according to time of onset. This is addressed in the literature by only a few studies with conflicting results. The aim of this study was to determine the demographic and clinical features of patients with non-segmental vitiligo and to establish the association between vitiligo and autoimmune diseases with a focus on time (...) of disease onset. A total of 224 vitiligo patients for whom complete medical records were available were evaluated retrospectively. Demographic data, scores on the Vitiligo Area Score Index (VASI), clinical features, vitiligo disease activity, repigmentation status, presence of any accompanying autoimmune disease, antinuclear antibody (ANA) titers, serum levels of glucose, thyroid-stimulating hormone (TSH), thyroxine (T4) hormone, anti-thyroid peroxidase (anti-TPO), and anti-thyroglobulin (anti-TG) were

2017 International Journal of Dermatology

196. Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses' Health Study 2. (PubMed)

Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses' Health Study 2. We aimed to determine the risk of alopecia areata (AA) and vitiligo associated with atopic dermatitis (AD) in a large cohort of US women, the Nurses' Health Study 2. We used logistic regression to calculate age- and multivariate-adjusted odds ratios to determine the risk of incident AA and vitiligo associated with AD diagnosed in or before 2009. A total of 87 406 and 87 447 participants were (...) included in the AA and vitiligo analyses, respectively. A history of AD in 2009 was reported in 11% of participants. There were 147 incident cases of AA and 98 incident cases of vitiligo over 2 years of follow-up. AD was associated with increased risk of developing AA (OR 1.80, 95% CI 1.18-2.76) and vitiligo (OR 2.14, 95% CI 1.29-3.54) in multivariate models. In this study of US women, AD was associated with increased risk of incident vitiligo and AA in adulthood.© 2017 John Wiley & Sons A/S. Published

Full Text available with Trip Pro

2017 Allergy

197. Twenty-year follow-up using a postal survey of childhood vitiligo treated with narrowband ultraviolet-B phototherapy. (PubMed)

Twenty-year follow-up using a postal survey of childhood vitiligo treated with narrowband ultraviolet-B phototherapy. 28117877 2018 08 13 2018 08 13 1365-2133 177 3 2017 09 The British journal of dermatology Br. J. Dermatol. Twenty-year follow-up using a postal survey of childhood vitiligo treated with narrowband ultraviolet B phototherapy. e60-e61 10.1111/bjd.15337 Lommerts J E JE Netherlands Institute for Pigment Disorders (NIPD), Department of Dermatology, Academic Medical Centre, Amsterdam (...) Netherlands Institute for Pigment Disorders (NIPD), Department of Dermatology, Academic Medical Centre, Amsterdam, the Netherlands. eng Letter 2017 07 25 England Br J Dermatol 0004041 0007-0963 IM Adult Age of Onset Child Female Follow-Up Studies Humans Male Retrospective Studies Treatment Outcome Ultraviolet Therapy methods Vitiligo radiotherapy 2017 1 25 6 0 2018 8 14 6 0 2017 1 25 6 0 ppublish 28117877 10.1111/bjd.15337

2017 British Journal of Dermatology

198. Is There a Relation between Vitamin D and Interleukin-17 in Vitiligo? A Cross-Sectional Study. (PubMed)

Is There a Relation between Vitamin D and Interleukin-17 in Vitiligo? A Cross-Sectional Study. High interleukin (IL)-17 contributes to vitiligo pathogenesis. Vitamin D has been assessed in vitiligo, with no reports targeting its relation to IL-17.To evaluate a possible regulatory effect of vitamin D on IL-17 and their relation to disease activity in vitiligo.This study included 30 vitiligo patients and 40 controls evaluated for IL-17 and vitamin D serum levels by ELISA technique.IL-17 (...) was significantly higher (p = 0.001) whereas vitamin D was found to be lower among the patients (p < 0.001). Multivariable regression was performed to evaluate the relationship between IL-17 and vitamin D levels with the demographic data on the patients, revealing a nonsignificant relationship (p > 0.05). A significant positive correlation was noted between vitamin D levels and disease duration.Vitamin D represents a potential player in the pathogenesis of vitiligo. Its possible regulatory relation to IL-17

Full Text available with Trip Pro

2017 Dermatology

199. Study of efficacy and safety of noncultured, extracted follicular outer root sheath cell suspension transplantation in the management of stable vitiligo. (PubMed)

Study of efficacy and safety of noncultured, extracted follicular outer root sheath cell suspension transplantation in the management of stable vitiligo. Noncultured, extracted follicular outer root sheath suspension (NC-EHF-ORS-CS) is a recently introduced technique for the treatment of stable vitiligo.To study the clinical efficacy of this technique and to determine the viability and cell composition of the suspension.Twenty-five patients with stable vitiligo were included in this prospective (...) and immunocytochemistry, respectively.At 6 months, the mean (±SD) repigmentation was 52 ± 25.1%, and >75% repigmentation was seen in 8/25 (32%) patients. Mean percentage cell viability of the suspension was 80 ± 17.2% with a mean concentration of CD200 + and S100 + cells being 7.91 ± 8.68% and 9.93 ± 1.22% (n = 3), respectively. Recipient site infection was seen in 4 of 25 (16%) patients and a color mismatch in 11 of 25 (44%) patients.NC-EHF-ORS-CS is a useful minimally invasive therapy for vitiligo.© 2017

2017 International Journal of Dermatology

200. Vitiligo Skin: Exploring the Dermal Compartment. (PubMed)

Vitiligo Skin: Exploring the Dermal Compartment. There is an increasing interest in the apparently normal skin in vitiligo. Altered expression of the adhesion molecule E-cadherin and persistent deregulated intracellular redox status that promotes the acquisition of a stress-induced senescent phenotype in melanocytes of normally pigmented skin from patients with vitiligo have been described. Growing evidence has shown that such cellular and functional alterations are not necessarily restricted (...) to melanocytes but may be extended to other cutaneous cell populations in both lesional and nonlesional areas. However, whether dermal fibroblasts exhibit related alterations that may contribute to the defects associated with melanocytes in vitiligo is not known. Here we reveal within the dermal compartment cells a myofibroblast phenotype and a predisposition to premature senescence, indicating the existence of altered cross-talk between dermal and epidermal components that may affect melanocyte

2017 Journal of Investigative Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>